Literature DB >> 35635632

LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?

Lamija Ferhatbegović1, Denis Mršić2, Sabina Kušljugić3, Belma Pojskić4.   

Abstract

PURPOSE OF REVIEW: Low-density lipoprotein cholesterol (LDL-C) is the most important causal risk factor for atherosclerotic cardiovascular disease (ASCVD). This article reviews why LDL-C remains overlooked and underestimated despite numerous studies that have proved its role. RECENT
FINDINGS: Recently published EAS/ESC Guidelines for dyslipidemia and EAS Guidelines for prevention set new targets for LDL-C levels in primary and secondary prevention of ASCVD. These guidelines are based on data from large studies and meta-analyzes that have shown that lower LDL-C also means lower cardiovascular event rates. Real-life experience published in registries worldwide has shown us that the guidelines have not been translated to everyday clinical practice, meaning that a significant number of patients are undertreated and have LDL-C levels well above target. Potential reasons for the abovementioned are poor adherence and education of the patient and physician and health care system related factors. Implementation of the latest version of guidelines will require continuous patient and physicians education, as well as a shared decision-making process between physician and patient.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Low-density lipoprotein cholesterol; atherosclerotic cardiovascular disease; lipid-lowering therapy; patient adherence

Mesh:

Substances:

Year:  2022        PMID: 35635632     DOI: 10.1007/s11883-022-01037-3

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.967


  44 in total

Review 1.  A century of cholesterol and coronaries: from plaques to genes to statins.

Authors:  Joseph L Goldstein; Michael S Brown
Journal:  Cell       Date:  2015-03-26       Impact factor: 41.582

2.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

Review 3.  The early years of lipoprotein research: from discovery to clinical application.

Authors:  Patty W Siri-Tarino; Ronald M Krauss
Journal:  J Lipid Res       Date:  2016-07-29       Impact factor: 5.922

Review 4.  Statins and LDL-cholesterol lowering: an overview.

Authors:  Erik Stroes
Journal:  Curr Med Res Opin       Date:  2005       Impact factor: 2.580

5.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

6.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

7.  Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes.

Authors:  Bernard M Y Cheung; Ian J Lauder; Chu-Pak Lau; Cyrus R Kumana
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

8.  Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.

Authors:  J F Brensike; R I Levy; S F Kelsey; E R Passamani; J M Richardson; I K Loh; N J Stone; R F Aldrich; J W Battaglini; D J Moriarty
Journal:  Circulation       Date:  1984-02       Impact factor: 29.690

9.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Authors:  Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2018-11-07       Impact factor: 91.245

Review 10.  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.

Authors:  Brian A Ference; Henry N Ginsberg; Ian Graham; Kausik K Ray; Chris J Packard; Eric Bruckert; Robert A Hegele; Ronald M Krauss; Frederick J Raal; Heribert Schunkert; Gerald F Watts; Jan Borén; Sergio Fazio; Jay D Horton; Luis Masana; Stephen J Nicholls; Børge G Nordestgaard; Bart van de Sluis; Marja-Riitta Taskinen; Lale Tokgözoglu; Ulf Landmesser; Ulrich Laufs; Olov Wiklund; Jane K Stock; M John Chapman; Alberico L Catapano
Journal:  Eur Heart J       Date:  2017-08-21       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.